Last $139.90 USD
Change Today +1.44 / 1.04%
Volume 351.7K
BDX On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 5:15 PM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

becton dickinson and co (BDX) Snapshot

Open
$138.94
Previous Close
$138.46
Day High
$141.08
Day Low
$138.55
52 Week High
12/4/14 - $142.56
52 Week Low
02/3/14 - $105.21
Market Cap
27.1B
Average Volume 10 Days
1.2M
EPS TTM
$6.08
Shares Outstanding
193.4M
EX-Date
12/8/14
P/E TM
23.0x
Dividend
$2.40
Dividend Yield
1.60%
Current Stock Chart for BECTON DICKINSON AND CO (BDX)

becton dickinson and co (BDX) Related Businessweek News

View More BusinessWeek News

becton dickinson and co (BDX) Details

Becton, Dickinson and Company, a medical technology company, develops, manufactures, and sells medical devices, instrument systems, and reagents worldwide. The company’s BD Medical segment produces medical devices, such as needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; syringes and pen needles for use in the treatment of diabetes; prefillable drug delivery systems; anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; and generic prefilled injectables. Its BD Diagnostics segment provides products for the collection and transportation of diagnostics specimens; and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections, and cancers. This segment’s products include integrated systems for specimen collection; safety-engineered blood collection products and systems; automated blood and tuberculosis culturing systems; molecular testing systems; microorganism identification and drug susceptibility systems; liquid-based cytology systems; rapid diagnostic assays; microbiology laboratory automation; and plated media. The company’s BD Medical segment offers research and clinical tools, such as fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; diagnostic assays; and cell culture media supplements for biopharmaceutical manufacturing. It also develops technologies that address biological analysis protocols, including library preparation of next generation sequencing and genotyping applications. The company markets its products through independent distribution channels and sales representatives to healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.

30,619 Employees
Last Reported Date: 11/26/14
Founded in 1897

becton dickinson and co (BDX) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $985.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $690.2K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $721.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $900.8K
Executive Vice President
Total Annual Compensation: $605.7K
Compensation as of Fiscal Year 2014.

becton dickinson and co (BDX) Key Developments

Becton, Dickinson and Company Announces Executive Changes

On December 22, 2014, the Board of Directors of Becton, Dickinson and Company (BD) elected John E. Gallagher, age 41, to the new position of Vice President, Corporate Finance and Treasurer. In this position, Mr. Gallagher will serve as company's principal accounting officer, replacing Joseph Mercurio, who has moved to another position within BD. Mr. Gallagher previously served as company's Vice President and Treasurer from 2012 to 2013, and most recently as its Vice President, Business Planning and Analysis and Treasurer. Prior to joining the company, Mr. Gallagher served as Vice President, Financial Planning & Analysis at NBC Universal.

Becton, Dickinson and Company Enters into 364-Day Term Loan Agreement

On December 19, 2014, Becton, Dickinson and Company entered into a 364-day term loan agreement (the Term Loan Agreement), by and among BD, as borrower, Goldman Sachs Bank USA, as administrative agent (the Administrative Agent) and the lenders party thereto that provides for a $1.0 billion term loan facility (the Term Loan Facility). Proceeds of the Term Loan Facility may be used only to pay for (i) a portion of the cash consideration due in connection with BD's previously announced and currently pending acquisition of CareFusion Corporation, pursuant to an agreement and plan of merger, dated October 5, 2014, by and among BD, CareFusion and Griffin Sub Inc. and wholly owned subsidiary of BD (the Merger) and the financing transactions associated with the Merger (together with the Merger, the Transactions) and (ii) the fees and expenses associated with the Transactions.

BD Medical to Present Total Hospital Pharmacy Solutions at the 2014 American Society of Health-System Pharmacists Midyear Clinical Meeting

BD Medical is presenting its comprehensive solutions for the hospital pharmacy during the 49th American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting taking place December 7-11, 2014 at the Anaheim Convention Center in Orange County, California. Building on BD's legacy and commitment to supporting safety and efficiency in healthcare, the solutions on display at Booth #1101 demonstrate a cohesive approach to reducing the possibility of human error, protecting healthcare workers from occupational hazards, standardizing practice, streamlining workflow and increasing efficiency from medication preparation to delivery. The exhibit will provide an experiential view of BD's solutions developed to help combat against the difficult task pharmacy practice leaders face in balancing quality improvements, compounding legislations changes and drug shortages while continuing to meet cost reduction expectations. BD's experiential Booth #1101 will showcase: BD Cato Medication; Workflow Solutions; BD Diabetes Care and AutoShield Duo; BD Disposal Solutions; BD Enteral Syringe with BD UniVia, Connector; BD Medication Preparation Products; BD PhaSeal System; BD Simplist Prefilled Injectables; and Intelliport® System.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BDX:US $139.90 USD +1.44

BDX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Agilent Technologies Inc $41.13 USD -0.24
Astellas Pharma Inc ¥1,713 JPY +3.00
Boston Scientific Corp $13.13 USD +0.07
Illumina Inc $186.22 USD +2.72
Zimmer Holdings Inc $114.11 USD +0.64
View Industry Companies
 

Industry Analysis

BDX

Industry Average

Valuation BDX Industry Range
Price/Earnings 23.3x
Price/Sales 3.2x
Price/Book 5.3x
Price/Cash Flow 22.8x
TEV/Sales 2.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BECTON DICKINSON AND CO, please visit www.bd.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.